Revance Therapeutics Inc (NASDAQ: RVNC) stock enjoyed a major increase of 12.3% on 1/6/25. The shares closed at $3.47. Moreover, exceptionally high trading volume at 429% of normal accompanied the advance. Relative to the market the stock has been strong over the last nine months and has risen 12.7% during the last week.
Current PriceTarget Research Rating
Revance Therapeutics is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment